Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses

[1]  Dong Men,et al.  SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses , 2020, Nature Communications.

[2]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[3]  R. Schwartz,et al.  Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.

[4]  Lin Cheng,et al.  Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 , 2020, Nature Medicine.

[5]  Xinquan Wang,et al.  Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals , 2020, Immunity.

[6]  Kwok-Hung Chan,et al.  Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial , 2020, The Lancet.

[7]  N. Zhang,et al.  Epidemiological characteristics and clinical features of 32 critical and 67 noncritical cases of COVID-19 in Chengdu , 2020, Journal of Clinical Virology.

[8]  Dong Yang,et al.  Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  Juan Du,et al.  Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study , 2020, European Respiratory Journal.

[10]  Allen M. Khakshooy,et al.  CoViD-19 Immunopathology and Immunotherapy , 2020, Bioinformation.

[11]  Linqi Zhang,et al.  Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor , 2020, Nature.

[12]  Jie Zhou,et al.  Global profiling of SARS-CoV-2 specific IgG/ IgM responses of convalescents using a proteome microarray , 2020, medRxiv.

[13]  Guohong Deng,et al.  Viral Kinetics and Antibody Responses in Patients with COVID-19 , 2020, medRxiv.

[14]  O. Tsang,et al.  Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study , 2020, The Lancet Infectious Diseases.

[15]  W. Xia,et al.  Suppressed T cell-mediated immunity in patients with COVID-19: A clinical retrospective study in Wuhan, China , 2020, Journal of Infection.

[16]  Yuxin Shi,et al.  Clinical progression of patients with COVID-19 in Shanghai, China , 2020, Journal of Infection.

[17]  Kwok-Hung Chan,et al.  Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR Assay Validated In Vitro and with Clinical Specimens , 2020, Journal of Clinical Microbiology.

[18]  P. Niu,et al.  Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China , 2020, Cell Host & Microbe.

[19]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[20]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[21]  S. Lindstrom,et al.  First Case of 2019 Novel Coronavirus in the United States , 2020, The New England journal of medicine.

[22]  P. Vollmar,et al.  Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany , 2020, The New England journal of medicine.

[23]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[24]  Ralph S. Baric,et al.  Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus , 2020, Journal of Virology.

[25]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[26]  S. Lo,et al.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster , 2020, The Lancet.

[27]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[28]  O. Tsang,et al.  High neutralizing antibody titer in intensive care unit patients with COVID-19 , 2020, Emerging microbes & infections.

[29]  J. Sodroski,et al.  SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease , 2020, bioRxiv.

[30]  K. To,et al.  Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan , 2020, Emerging microbes & infections.

[31]  R. Baric,et al.  Receptor recognition by novel coronavirus from Wuhan: 2 An analysis based on decade-long structural studies of SARS 3 , 2020 .

[32]  Chuan Qin,et al.  Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. , 2019, JCI insight.

[33]  J. Joh,et al.  Immune Responses to Middle East Respiratory Syndrome Coronavirus During the Acute and Convalescent Phases of Human Infection , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  Zhiwei Chen,et al.  Tandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized mice , 2018, The Journal of clinical investigation.

[35]  Zhiwei Chen,et al.  Spatiotemporal interplay of severe acute respiratory syndrome coronavirus and respiratory mucosal cells drives viral dissemination in rhesus macaques , 2015, Mucosal Immunology.

[36]  Jincun Zhao,et al.  Virus-Specific Memory CD8 T Cells Provide Substantial Protection from Lethal Severe Acute Respiratory Syndrome Coronavirus Infection , 2014, Journal of Virology.

[37]  Jincun Zhao,et al.  T Cell Responses Are Required for Protection from Clinical Disease and for Virus Clearance in Severe Acute Respiratory Syndrome Coronavirus-Infected Mice , 2010, Journal of Virology.

[38]  P. Rod Dunbar,et al.  Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens , 2010, The Journal of experimental medicine.

[39]  D. Chaplin.  Overview of the immune response. , 2003, The Journal of allergy and clinical immunology.

[40]  B. Ni,et al.  Identification of a novel conserved HLA-A*0201-restricted epitope from the spike protein of SARS-CoV , 2009, BMC Immunology.

[41]  A. McMichael,et al.  T Cell Responses to Whole SARS Coronavirus in Humans1 , 2008, The Journal of Immunology.

[42]  J. Dai,et al.  Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. , 2008, Cytokine & growth factor reviews.

[43]  D. Ho,et al.  Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals , 2005, Journal of medical virology.

[44]  Jeng-Min Chiou,et al.  Neutralizing Antibody Response and SARS Severity , 2005, Emerging infectious diseases.

[45]  Y. Lau,et al.  Chemokine up-regulation in SARS-coronavirus–infected, monocyte-derived human dendritic cells , 2005, Blood.

[46]  D. Ho,et al.  Single Amino Acid Substitutions in the Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein Determine Viral Entry and Immunogenicity of a Major Neutralizing Domain , 2005, Journal of Virology.

[47]  Ruifu Yang,et al.  Response of Memory CD8+ T Cells to Severe Acute Respiratory Syndrome (SARS) Coronavirus in Recovered SARS Patients and Healthy Individuals1 , 2005, The Journal of Immunology.

[48]  Lucy A. Perrone,et al.  Severe Acute Respiratory Syndrome and the Innate Immune Responses: Modulation of Effector Cell Function without Productive Infection1 , 2005, The Journal of Immunology.

[49]  R. Weiss,et al.  Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with Pseudotypes , 2005, Emerging infectious diseases.

[50]  Lucy A. Perrone,et al.  Severe Acute Respiratory Syndrome and the Innate Immune Responses: Modulation of Effector Cell Function without Productive Infection , 2005 .

[51]  Huanghao Yang,et al.  T-Cell Epitopes in Severe Acute Respiratory Syndrome (SARS) Coronavirus Spike Protein Elicit a Specific T-Cell Immune Response in Patients Who Recover from SARS , 2004, Journal of Virology.

[52]  R. Gutzmer,et al.  A Tumor-Associated Glycoprotein That Blocks MHC Class II-Dependent Antigen Presentation by Dendritic Cells1 , 2004, The Journal of Immunology.

[53]  Weifeng Chen,et al.  T-Cell Epitopes in Severe Acute Respiratory Syndrome (SARS) Coronavirus Spike Protein Elicit a Specific T-Cell Immune Response in Patients Who Recover from SARS , 2004, Journal of Virology.

[54]  N. Mitchison.  T-cell–B-cell cooperation , 2004, Nature Reviews Immunology.

[55]  Xiaojun Xu,et al.  Immunological responses against SARS-coronavirus infection in humans. , 2004, Cellular & molecular immunology.

[56]  Zheng Zhang,et al.  [Characterization of peripheral dendritic cell subsets and its implication in patients infected with severe acute respiratory syndrome]. , 2004, Zhonghua yi xue za zhi.

[57]  G. Schuler,et al.  Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic Cells , 2002, The Journal of experimental medicine.

[58]  V. Maino,et al.  Normal human CD4+ memory T cells display broad heterogeneity in their activation threshold for cytokine synthesis. , 1998, Journal of immunology.

[59]  Dr Ferdiye Taner,et al.  The enzyme-linked immunosorbent assay (ELISA). , 1976, Bulletin of the World Health Organization.

[60]  A. Davies,et al.  Immune Responses , 1971, Nature.